Investors sentiment decreased to 1.47 in Q2 2019. Its down 0.20, from 1.67 in 2019Q1. It dived, as 22 investors sold Dermira, Inc. shares while 23 reduced holdings. 14 funds opened positions while 52 raised stakes. 46.14 million shares or 2.85% less from 47.50 million shares in 2019Q1 were reported.
Parametric Port Ltd Liability Corp, a Washington-based fund reported 37,293 shares. Wellington Group Inc Llp, a Massachusetts-based fund reported 5.55M shares. Benjamin F Edwards And Co invested in 0% or 100 shares. Trellus Mgmt Com Limited Liability Company stated it has 0.78% in Dermira, Inc. (NASDAQ:DERM). Paradigm Cap Mgmt Inc has invested 0.22% in Dermira, Inc. (NASDAQ:DERM). 29,941 were reported by Manufacturers Life Communications The. Platinum Mgmt Limited owns 116,325 shares or 0.03% of their US portfolio. Swiss Bancorporation owns 82,900 shares. Trexquant L P holds 0.01% or 13,590 shares. Art Advsr Ltd accumulated 0.03% or 61,075 shares. Meeder Asset Mngmt holds 0% or 582 shares. Moreover, Balyasny Asset Mgmt has 0% invested in Dermira, Inc. (NASDAQ:DERM). Tower Rech Ltd (Trc) invested 0% in Dermira, Inc. (NASDAQ:DERM). Ny State Common Retirement Fund holds 47,700 shares. Millennium Mngmt Ltd Liability holds 48,277 shares.
Since August 15, 2019, it had 1 insider buy, and 0 sales for $199,998 activity.
The stock of Dermira, Inc. (NASDAQ:DERM) is a huge mover today! The stock decreased 2.91% or $0.24 during the last trading session, reaching $8.02. About 854,984 shares traded. Dermira, Inc. (NASDAQ:DERM) has declined 4.55% since December 4, 2018 and is downtrending. It has underperformed by 4.55% the S&P500.
The move comes after 8 months negative chart setup for the $437.26M company. It was reported on Dec, 4 by Barchart.com. We have $7.30 PT which if reached, will make NASDAQ:DERM worth $39.35M less.
Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 25. They expect $-1.34 EPS, up 21.18 % or $0.36 from last year’s $-1.7 per share. After $-1.06 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 26.42 % negative EPS growth.
More notable recent Dermira, Inc. (NASDAQ:DERM) news were published by: Finance.Yahoo.com which released: “Did You Manage To Avoid Dermira’s (NASDAQ:DERM) Painful 63% Share Price Drop? – Yahoo Finance” on May 08, 2019, also Nasdaq.com with their article: “New Mountain Finance Corp (NMFC) Q3 2019 Earnings Call Transcript – Nasdaq” published on November 07, 2019, Nasdaq.com published: “The 4th Revolution: Two-and-a-Half Centuries of Innovation – Nasdaq” on November 08, 2019. More interesting news about Dermira, Inc. (NASDAQ:DERM) were released by: Seekingalpha.com and their article: “Stocks To Watch: Retailers, Dubai Airshow And Cybertrucks – Seeking Alpha” published on November 16, 2019 as well as Nasdaq.com‘s news article titled: “Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks – Nasdaq” with publication date: November 07, 2019.
Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $437.26 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.